Blueprint Medicines Corporation

Blueprint reported first-quarter total revenues of $149.4 million, all from AYVAKIT net product sales, with $129.4 million in the US and $20 million outside the US. Management said AYVAKIT revenue grew 61% year over year. Gross-to-net was helped by a free-goods rate that is now well below 10%, and the company raised full-year AYVAKIT net product revenue guidance to $700 million-$720 million. On expenses, R&D increased quarter over quarter due to elenestinib and BLU-808 studies, while SG&A was flat versus the prior quarter; the company said modest increases in both R&D and SG&A should continue. Blueprint ended with a strong cash position of $900 million and reiterated that operating cash burn should decline significantly on an annual basis.

Kate Haviland framed the quarter as evidence that Blueprint is executing on a long-term plan built around commercial excellence, pipeline innovation, and a durable financial profile. She emphasized that AYVAKIT is still early in a multi-billion-dollar systemic mastocytosis opportunity and that the company is raising guidance because the underlying demand trend remains strong. She also highlighted progress in the pipeline, especially BLU-808 and elenestinib, while saying the company does not expect material impact from tariffs or near-term FDA staffing changes.

Mike Landsittel said Q1 revenue was $149.4 million from AYVAKIT sales and that guidance was raised to $700 million-$720 million for the year based on stronger fundamentals and better visibility into free goods. He noted quarter-over-quarter R&D increased due to clinical work in elenestinib and BLU-808, while SG&A was flat in Q1 but should rise modestly as Blueprint invests more in the pipeline and AYVAKIT promotion. He also said the company expects operating cash burn to decline significantly on an annual basis and ended the quarter with $900 million in cash.

Analysts focused on whether Q2 would show a rebound after Q1’s seasonal headwinds, how durable the sub-10% free-goods rate is, and whether international growth and reimbursement could accelerate later in the year. Management said the updated full-year guide already reflects seasonality and that underlying patient growth remains strong, while Q3 should benefit from an order-day timing make-up. On ex-US, they said Germany is the only market with ISM reimbursement today, more markets should come online this year, and larger contributions are more likely next year and beyond.